Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 15/20 | 0.61 |
| ▸ | TGM1 | P22735 | 13/20 | 0.61 |
| ▸ | F13A1 | P00488 | 12/20 | 0.61 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13269785 | 0.85 | MEN1 (0.59) | TGM2TGM1F13A1TGM3MEN1 | |
| SCHEMBL6237772 | 0.83 | MEN1 (0.61) | TGM2TGM1F13A1TGM3MEN1 | |
| SCHEMBL379160 | 0.83 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL7393652 | 0.83 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL4814264 | 0.83 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL3970912 | 0.83 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2954213 | 0.82 | TSHR (0.63) | TGM2TGM1F13A1TGM3MEN1 | |
| SCHEMBL15011579 | 0.81 | MEN1 (0.73) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| Bicarbonate SCHEMBL4357688 | 0.81 | MEN1 (0.73) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL10064223 | 0.81 | TGM2 (0.70) | TGM2TGM1F13A1TGM3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102448958-B | Pyrimidyl and 1,3,5-triazines base benzimidazole sulfonamides and its purposes in cancer therapy | VETDC, INC. (US) | 2015-10-21 | — | — | CN | disclosed |
| EP-2411387-B1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | VETDC INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-9108980-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150038486-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | ELANCO US INC. | 2015-02-05 | — | — | US | disclosed |
| US-8772287-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130289016-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | ELANCO US INC. | 2013-10-31 | — | — | US | disclosed |
| US-8461158-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | PATHWAY THERAPEUTICS INC. (US) | 2013-06-11 | — | — | US | disclosed |
| CN-102448958-A | Pyrimidinyl and 1,3, 5-triazinyl benzimidazole sulfonamides and their use in the treatment of cancer | PATHWAY THERAPEUTICS LTD | 2012-05-09 | — | — | CN | disclosed |
| EP-2411387-A2 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | Pathway Therapeutics, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010110685-A2 | PYRIMDDINYL AND 1,3,5-TRIAZINYL BENZIMTOAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | WO | disclosed |
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | TGM2 552/4885TGM1 286/4885F13A1 3018/4885 |
| US-20150038486-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | TGM2 552/4885TGM1 286/4885F13A1 3018/4885 |
| US-20130289016-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | TGM2 552/4885TGM1 286/4885F13A1 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.